Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
Author Contributions
Conflicts of Interest
References
- Migden, M.R.; Rischin, D.; Schmults, C.D.; Guminski, A.; Hauschild, A.; Lewis, K.D.; Chung, C.H.; Hernandez-Aya, L.; Lim, A.M.; Chang, A.L.S.; et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2018, 379, 341–351. [Google Scholar] [CrossRef]
- Grob, J.J.; Gonzalez, R.; Basset-Seguin, N.; Vornicova, O.; Schachter, J.; Joshi, A.; Meyer, N.; Grange, F.; Piulats, J.M.; Bauman, J.R.; et al. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J. Clin. Oncol. 2020, 38, 2916–2925. [Google Scholar] [CrossRef]
- Rischin, D.; Porceddu, S.; Day, F.; Brungs, D.P.; Christie, H.; Jackson, J.E.; Stein, B.N.; Su, Y.B.; Ladwa, R.; Adams, G.; et al. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2025. [Google Scholar] [CrossRef]
- Karia, P.S.; Jambusaria-Pahlajani, A.; Harrington, D.P.; Murphy, G.F.; Qureshi, A.A.; Schmults, C.D. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J. Clin. Oncol. 2014, 32, 327–334. [Google Scholar] [CrossRef]
- Bowe, C.M.; Houlton, S.; Walsh, S. Comparison of the eighth edition of the TNM and Brigham Women’s Hospital staging systems for cutaneous squamous cell carcinoma of the head and neck: A six-year review. Br. J. Oral. Maxillofac. Surg. 2020, 58, 1158–1163. [Google Scholar] [CrossRef] [PubMed]
- Stratigos, A.J.; Garbe, C.; Dessinioti, C.; Lebbe, C.; van Akkooi, A.; Bataille, V.; Bastholt, L.; Dreno, B.; Dummer, R.; Fargnoli, M.C.; et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023. Eur. J. Cancer 2023, 193, 113251. [Google Scholar] [CrossRef] [PubMed]
- Network NCC. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Caner (Version 2.2025). 2025. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465 (accessed on 26 June 2025).
- Steijlen, O.F.M.; Pozza, L.; Traets, J.J.H.; Rentroia-Pacheco, B.; Eggermont, C.J.; Bellomo, D.; Alex, S.; Patel, V.A.; Mooyaart, A.L.; Hollestein, L.M.; et al. Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model: Results from 2 nationwide nested case-control studies. J. Am. Acad. Dermatol. 2025. [Google Scholar] [CrossRef]
- Shahwan, K.T.; Walker, T.D.; Diede, C.; Nikahd, M.; Aasi, S.Z.; Bordeaux, J.S.; Christensen, S.R.; Chung, C.; Elston, D.M.; Grant-Kels, J.M.; et al. Grading differentiation in cutaneous squamous cell carcinoma: A modified Delphi consensus panel. J. Am. Acad. Dermatol. 2025. [Google Scholar] [CrossRef]
- Stratigos, A.J.; Garbe, C.; Dessinioti, C.; Lebbe, C.; van Akkooi, A.; Bataille, V.; Bastholt, L.; Dreno, B.; Dummer, R.; Fargnoli, M.C.; et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023. Eur. J. Cancer 2023, 193, 113252. [Google Scholar] [CrossRef]
- Work, G.; Invited, R.; Kim, J.Y.S.; Kozlow, J.H.; Mittal, B.; Moyer, J.; Olenecki, T.; Rodgers, P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 2018, 78, 560–578. [Google Scholar] [CrossRef] [PubMed]
- Ruiz, E.S.; Karia, P.S.; Besaw, R.; Schmults, C.D. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2019, 155, 819–825. [Google Scholar] [CrossRef]
- Ruiz, E.S.; Kus, K.J.B.; Smile, T.D.; Murad, F.; Zhou, G.; Ilori, E.O.; Schoenfeld, J.D.; Margalit, D.N.; Tishler, R.B.; Vidimos, A.T.; et al. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. J. Am. Acad. Dermatol. 2022, 87, 87–94. [Google Scholar] [CrossRef] [PubMed]
- Porceddu, S.V.; Bressel, M.; Poulsen, M.G.; Stoneley, A.; Veness, M.J.; Kenny, L.M.; Wratten, C.; Corry, J.; Cooper, S.; Fogarty, G.B.; et al. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. J. Clin. Oncol. 2018, 36, 1275–1283. [Google Scholar] [CrossRef] [PubMed]
- Porceddu, S.V.; Connolly, E.; Bressel, M.; Wratten, C.; Liu, H.Y.; Rischin, D. Prognostic Subgroups for Disease-Free Survival in Head and Neck Cutaneous Squamous Cell Carcinoma. JAMA Otolaryngol. 2025; in press. [Google Scholar]
- Kim, Y.; Lehrer, E.J.; Wirth, P.J.; Khesroh, E.A.; Brewer, J.D.; Billingsley, E.M.; Zaorsky, N.G.; Lam, C. Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2022, 86, 1246–1257. [Google Scholar] [CrossRef]
- Jambusaria-Pahlajani, A.; Miller, C.J.; Quon, H.; Smith, N.; Klein, R.Q.; Schmults, C.D. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of outcomes. Dermatol. Surg. 2009, 35, 574–585. [Google Scholar] [CrossRef]
- Available online: https://www.isrctn.com/ISRCTN54806122 (accessed on 31 July 2025).
- Hughes, B.G.M.; Guminski, A.; Bowyer, S.; Migden, M.R.; Schmults, C.D.; Khushalani, N.I.; Chang, A.L.S.; Grob, J.J.; Lewis, K.D.; Ansstas, G.; et al. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J. Am. Acad. Dermatol. 2025, 92, 68–77. [Google Scholar] [CrossRef]
- Ferrarotto, R.; Amit, M.; Nagarajan, P.; Rubin, M.L.; Yuan, Y.; Bell, D.; El-Naggar, A.K.; Johnson, J.M.; Morrison, W.H.; Rosenthal, D.I.; et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin. Cancer Res. 2021, 27, 4557–4565. [Google Scholar] [CrossRef]
- Ferrarotto, R.; Nagarajan, P.; Maronge, J.M.; Johnson, J.M.; Rosenthal, D.I.; Myers, J.N.; Gross, N.D. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol. 2023, 149, 847–849. [Google Scholar] [CrossRef]
- Gross, N.D.; Miller, D.M.; Khushalani, N.I.; Divi, V.; Ruiz, E.S.; Lipson, E.J.; Meier, F.; Su, Y.B.; Swiecicki, P.L.; Atlas, J.; et al. Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet. Oncol. 2023, 24, 1196–1205. [Google Scholar] [CrossRef]
- Gross, N.D.; Miller, D.M.; Khushalani, N.I.; Divi, V.; Ruiz, E.S.; Lipson, E.J.; Meier, F.; Su, Y.B.; Swiecicki, P.L.; Atlas, J.; et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2022, 387, 1557–1568. [Google Scholar] [CrossRef] [PubMed]
- Lim, A.M.; Baker, B.; Lion, P.; Angel, C.M.; Simmons, J.; Jackson, B.; Magarey, M.; Webb, A.; Nguyen, K.; Hudson, J.; et al. Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial. Cancers 2025, 17, 1727. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://clinicaltrials.gov/study/NCT06568172 (accessed on 31 July 2025).
- Blank, C.U.; Lucas, M.W.; Scolyer, R.A.; van de Wiel, B.A.; Menzies, A.M.; Lopez-Yurda, M.; Hoeijmakers, L.L.; Saw, R.P.M.; Lijnsvelt, J.M.; Maher, N.G.; et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N. Engl. J. Med. 2024, 391, 1696–1708. [Google Scholar] [CrossRef] [PubMed]
Extracapsular extension in ≥1 node at least 20 mm in diameter |
Involvement of ≥3 nodes |
In-transit metastases |
T4 primary tumour |
Radiologic/clinical involvement of named nerves |
Local recurrence with at least one other adverse feature of ≥N2b, ≥T3 lesion, or poorly differentiated disease at least 20 mm in diameter |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lim, A.M.; Porceddu, S.; Rischin, D. Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma. Curr. Oncol. 2025, 32, 459. https://doi.org/10.3390/curroncol32080459
Lim AM, Porceddu S, Rischin D. Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma. Current Oncology. 2025; 32(8):459. https://doi.org/10.3390/curroncol32080459
Chicago/Turabian StyleLim, Annette M., Sandro Porceddu, and Danny Rischin. 2025. "Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma" Current Oncology 32, no. 8: 459. https://doi.org/10.3390/curroncol32080459
APA StyleLim, A. M., Porceddu, S., & Rischin, D. (2025). Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma. Current Oncology, 32(8), 459. https://doi.org/10.3390/curroncol32080459